Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that its Ultra ...

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that the U.S.

Adagio Medical (Nasdaq:ADGM) announced today that it received FDA investigational device exemption (IDE) to expand its ...

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac ...

Patients suffering from refractory ventricular tachycardia, a life-threating heart condition, who are not suitable for ...

Adagio Medical Holdings Inc. (NASDAQ:ADGM) said it has received Investigational Device Exemption (IDE) authorization from the ...

In a remarkable clinical achievement, Kauvery Hospital, Alwarpet, successfully treated a 71-year-old man with multiple ...

Johns Hopkins researchers built a virtual replica of each patient’s heart, simulated the electrical circuits causing a life-threatening arrhythmia, and used those simulations to guide a real-world ...

Working with "digital twins" of patients' hearts, doctors have improved cardiac ablation outcomes for patients with life-threatening arrhythmias. In the first clinical trials for cardiac digital twins ...

Corify Care announced today that it received FDA clearance for its Acorys imageless, non-invasive cardiac mapping platform.

Scientists at Johns Hopkins University are creating virtual replicas of patients’ hearts so they can test how to fix a life-threatening irregular heartbeat before treating the real organ.

A small clinical trial suggests the technology can help physicians perform life-saving surgeries more efficiently and safely ...